Our results showed for the first time that SK2 is involved in ovarian cancer cell migration and that plasma membrane SK2 plays a key function in LPA‐induced cell migration, suggesting SK2 as potential target that should be inhibited in context of the tertiary prevention after the end of chemotherapy cycles. This evidence concerns the gene KCNN2 and ovarian cancer.